Good Lifestyle

Millions of Americans havebeen vaccinated against Covid In recent months. Although we know that these vaccines are safe, we were mainly in the dark when it comes to their long-term effectiveness because vaccines had not been long enough to gather enough data. Now, the recent test data have just been published by Pfizer and give an indication of the life of their vaccine in effect in the test participants. Read to find out how long the Pfizer vaccine protects you and for more vaccination guidance, discoverThe first thing you need to do after you are fully vaccinated, say experts.

The Coronavirus Pfizer and Biontech vaccine seems to be always very effective in protecting individualsagainst symptomatic cases of COVID For at least six months after the second dose, according to a study published by the companies on April 1st. Researchers examined first instance data of more than 46,000 participants and found that on the 927 trial participants who were infected with COVID more than a week after their second dose, only 77 had received the real vaccine. at 850 who had received a placebo. This shows that the anti-Pfizer-Biontech vaccine is "very effective" with a vaccine efficiency of 91.3% against the symptomatic covidator seven days at least six months after the second dose.

"This is an important step to further confirm the high efficiency and good security data we have seen so far, especially in long-term follow-up," ","Ugur sahin, MD, CEO and co-founder of Biontech, said in a statement. And for more on the future of vaccination,The Pfizer CEO says how many times you will need a Covid vaccine.

The study revealed that the vaccine was even more effective in protecting the severity of COVID for at least six months. According to researchers, the vaccine is 100% effective in the prevention of serious illnesses as defined by the US Centers for Disease Control and Prevention (CDC) and 95.3% effective to whatsoever as defined by the Food and Drug Administration (FDA). By using the CDC definition, 32 cases of serious illness were observed in the placebo group compared to any of the participants who were truly vaccinated. By FDA standards, 21 serious COVID cases were reported in the placebo group compared to only one of the vaccinated group. And for more, you need to know vaccination,The CDC says do not do it before 4 weeks after being vaccinated.

Emerging coronavirus variants Have caused significant concerns in recent months, even among the distribution of still expanding vaccines. One of the main areas of concern was whether the mutations of these variants would cause existing Covid vaccines to lose their effectiveness. But according to the new study of Pfizer and Biontech, it does not seem to be a problem. The researchers had 800 participants enrolled in South Africa, where Variant B.1.351 is originary and prevalent. They found that nine COVID cases emerged from participants (six of which were Variant B.1.351), while in the placebo group - indicating a 100% vaccine effectiveness against this disturbing variant of South Africa.

According to Sahin, these data provide "the first clinical outcomes that a vaccine can effectively protect against current variants, a critical factor in achieving the immunity of the flock and ending this pandemic for the world's population". And for more COVID updates,Sign up for our daily newsletter.

Currently, the three vaccines available in the United States are being distributed under an emergency authorization of the FDA. However, for full approval, vaccine manufacturers must apply for a biology license, which requires long-term safety and efficiency data of at least six months. As a spokesman for Pfizer-Biontech, told Fox News in January, companiesPlan to submit a biology license application In the first half of 2021, and this new study shows a promising lead.

"These data confirm the favorable efficiency and security profile of our vaccine and position us to submit a biology license application to the US FDA,"Albert Bourla, PhD, President and Chief Executive Officer of Pfizer, said in a declaration of the new study. "The high efficiency of vaccines observed up to six months after a second dose and prearant variant in South Africa offers additional confidence in the overall effectiveness of our vaccine." And for vaccine reactions to prepare, learnThe effect on one side that is much more common with Pfizer, data data.